From January 1, 2024 to March 31, 2024, the company has repurchased 239,555 shares, representing 0.003912% for CNY 10 million. With this, the company has completed the repurchase of 14,351,878 shares, representing 0.23% for CNY 634.67 million under the buyback announced on May 15, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
47.23 CNY | +0.15% | +2.32% | +4.42% |
04-26 | Hengrui Pharma Gets Nod to Trial Insulin Aspart Injection; Shares Up 3% | MT |
04-17 | Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.42% | 41.62B | |
+33.43% | 700B | |
+26.43% | 569B | |
-5.12% | 358B | |
+19.59% | 330B | |
+4.89% | 287B | |
+14.32% | 236B | |
+5.79% | 202B | |
-9.49% | 197B | |
+4.26% | 161B |
- Stock Market
- Equities
- 600276 Stock
- News Jiangsu Hengrui Medicine Co., Ltd.
- Tranche Update on Jiangsu Hengrui Medicine Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023.